XMHQ - ETF AI Analysis
Top Page
Invesco S&P MidCap Quality ETF (XMHQ)
Rating:74Outperform
Price Target:―
Positive Factors
Strong Overall Performance
The ETF has shown solid gains so far this year and in recent months, indicating positive momentum in its mid-cap quality strategy.
High-Quality, Strong-Performing Top Holdings
Several of the largest positions, such as TechnipFMC, nVent Electric, and Carpenter Technology, have delivered strong returns, helping drive the fund’s results.
Diversified Sector Exposure Within U.S. Mid-Caps
Holdings are spread across industrials, technology, health care, financials, and other sectors, which helps reduce the impact of weakness in any single industry.
Negative Factors
Heavy U.S.-Only Exposure
Almost all assets are invested in U.S. companies, so the fund offers little protection if the U.S. market faces broad challenges.
Meaningful Position Concentration
The top holdings each make up a noticeable share of the portfolio, which increases the impact that problems at a few companies could have on the ETF.
Some Lagging Holdings Among Top Positions
At least one major holding, such as Medpace Holdings, has shown weak performance this year, which can drag on the fund’s overall returns.
XMHQ vs. SPDR S&P 500 ETF (SPY)
AUM5.64B
RegionNorth America
Expense Ratio0.25%
Beta0.93
IssuerInvesco
Inception DateDec 01, 2006
Dividend Yield0.54%
Asset ClassEquity
Index TrackedS&P MidCap 400 Quality Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume147,991
30 Day Avg. Volume180,414
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
134.61Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering81
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XMHQ Summary
XMHQ is the Invesco S&P MidCap Quality ETF, which follows the S&P MidCap 400 Quality Index. It invests in medium‑sized U.S. companies that score well on measures of financial strength and business stability. The fund is spread across sectors like industrials, technology, health care, and finance, and holds names such as Illumina and United Therapeutics. Someone might consider XMHQ for long‑term growth and diversification, while focusing on companies that are generally higher quality than the average mid‑cap stock. A key risk is that mid‑cap stocks can be more volatile than large companies, so the ETF’s value can go up and down with the market.
How much will it cost me?The Invesco S&P MidCap Quality ETF (XMHQ) has an expense ratio of 0.25%, meaning you’ll pay $2.50 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it tracks a specialized index focused on mid-cap companies with strong quality metrics. It’s designed to offer targeted exposure to financially healthy mid-cap stocks.
What would affect this ETF?The Invesco S&P MidCap Quality ETF (XMHQ) could benefit from economic growth in the U.S., particularly in sectors like Industrials and Health Care, which make up a significant portion of its holdings. However, rising interest rates or economic slowdowns could negatively impact mid-cap companies, especially those in cyclical sectors like Consumer Cyclical and Financials. Regulatory changes or shifts in sector-specific trends could also influence the performance of its top holdings, such as Comfort Systems and Medpace Holdings.
XMHQ Top 10 Holdings
XMHQ leans heavily into U.S. industrials and health care, and a handful of mid-cap standouts are steering the ship. TechnipFMC and Carpenter Technology have been rising steadily, giving the fund a strong industrial backbone. Illumina and Medpace add a powerful health care tilt, with both names showing solid, if sometimes overheated, momentum. On the flip side, nVent Electric and Evercore have been more mixed lately, occasionally dragging on returns. Overall, the ETF is concentrated in quality U.S. mid-caps rather than flashy Big Tech, aiming for durable growth over quick thrills.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| TechnipFMC | 4.14% | $233.21M | $27.30B | 111.98% | 80 Outperform | |
| Everpure | 4.02% | $226.62M | $29.93B | 70.88% | 64 Neutral | |
| Illumina | 3.81% | $214.59M | $28.38B | 102.35% | 71 Outperform | |
| Medpace Holdings | 3.16% | $178.21M | $16.49B | 33.94% | 79 Outperform | |
| nVent Electric | 2.99% | $168.27M | $26.66B | 82.89% | 76 Outperform | |
| Curtiss-Wright | 2.98% | $167.87M | $25.54B | 41.86% | 74 Outperform | |
| Carpenter Technology | 2.81% | $158.20M | $28.35B | 125.48% | 75 Outperform | |
| Manhattan Associates | 2.76% | $155.46M | $11.38B | -4.66% | 75 Outperform | |
| Exelixis | 2.61% | $146.92M | $13.40B | 41.57% | 78 Outperform | |
| United Therapeutics | 2.50% | $141.01M | $23.11B | 76.30% | 79 Outperform |
XMHQ Technical Analysis
Positive
―
Price Trends
113.02
Positive
109.80
Positive
107.13
Positive
Market Momentum
1.75
Negative
70.88
Negative
90.42
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XMHQ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 115.06, equal to the 50-day MA of 113.02, and equal to the 200-day MA of 107.13, indicating a bullish trend. The MACD of 1.75 indicates Negative momentum. The RSI at 70.88 is Negative, neither overbought nor oversold. The STOCH value of 90.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XMHQ.
XMHQ Peer Comparison
Comparison Results
Performance Comparison
XMHQ
Invesco S&P MidCap Quality ETF
119.33
17.41
17.08%
FMDE
Fidelity Enhanced Mid Cap ETF
―
―
―
XMMO
Invesco S&P MidCap Momentum ETF
―
―
―
JHMM
John Hancock Multifactor Mid Cap ETF
―
―
―
DON
WisdomTree U.S. MidCap Dividend Fund
―
―
―
IVOO
Vanguard S&P Mid-Cap 400 ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents